Analytical Data
-
Gene name
SNAI1
- Application
-
Alternative Names
SLUGH2; SNA; SNAH; Snail 1 Zinc Finger Protein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95863
-
Expression Region
Met1~Arg264
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SNAI1, a pivotal transcription factor, plays a crucial role in epithelial-mesenchymal transition (EMT), a process essential for embryonic development, tissue repair, and cancer metastasis. Research has shown that SNAI1 mediates the downregulation of epithelial markers and the upregulation of mesenchymal markers, facilitating cell migration and invasion. Its involvement in various pathological conditions, particularly in the context of cancer, has garnered significant attention in the scientific community. Studies indicate that aberrant SNAI1 expression contributes not only to tumor progression but also to drug resistance, highlighting its potential as a therapeutic target. The exploration of SNAI1-recombinant proteins focuses on understanding its mechanistic role in EMT and related pathways. By producing and characterizing these recombinant proteins, researchers aim to elucidate SNAI1's interaction with other cellular components, assess its functional implications in cell behavior, and evaluate its potential as a biomarker for cancer prognosis. Advances in recombinant protein technology allow for the generation of active SNAI1 proteins, facilitating in vitro and in vivo studies that further unravel the complexities of its role in developmental biology and disease. This research is essential for developing innovative therapeutic strategies aimed at modulating SNAI1 activity in various diseases, particularly in enhancing the efficacy of existing cancer treatments. Overall, the characterization of SNAI1-recombinant proteins is pivotal for both basic research and clinical applications, offering insights into the fundamental processes that govern cellular dynamics and disease progression.
